Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Miret Campos Varela, Isabel
  • Villagrasa Vilella, Ares Aurora
  • Simon-Talero Horga, Macarena
  • Riveiro Barciela, Maria del Mar
  • Ventura Cots, Meritxell
  • Álvarez López, Patricia
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan
  • Barreira Diaz, Ana
  • Biagetti Biagetti, Betina
  • Camps-Relats, Laura
  • Cocera Rodriguez, Raul
  • Dopazo Taboada, Cristina
  • Fernandez Pujol, Andrea
  • Jimenez Hernandez, Cesar
  • Matarín Jiménez, Maria del Mar
  • Jofra, Mariona
  • Gil, Clara
  • Gomez Gavara, Concepción
  • Guevara Cubas, Jorge Alonso
  • Lobo Alvarez, Beatriz
  • Malagelada Prats, Carolina
  • Martínez Campreciós, Joan
  • Pando Rau, Elizabeth
  • Perez-Lopez, Ana
  • Prio, Alba
  • Rivera Esteban, Jesus Manuel
  • Romero, Alba
  • Tasayco Huaman, Stephanie Solange
  • Vidal Gonzalez, Judit
  • Vidal Piñeiro, Laura
  • Minguez Rosique, Beatriz
  • Genescà Ferrer, Joan
  • Ciudin Mihai, Andreea
  • Barber Caselles, Claudia
  • Augustin Recio, Salvador
  • Aguilera Castro, Lara
  • Guagnozzi, Danila
  • Miret Alomar, Enric
  • Pigrau Pastor, Marc
  • Mayorga Ayala, Luis Fernando
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury, Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JG is a recipient of a Research Intensification grant from the Instituto de Salud Carlos III, Spain. MST and MVC are recipients of a Juan Rodés grant from the Instituto de Salud Carlos III. The work was partially funded by grants PI17/00310, PI18/00947, PI18/00961, and PI19/00330 from Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future” – Una manera de hacer Europa). CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH

  • Bravo, Miren|||0000-0001-5889-9125
  • Raurell, Imma|||0000-0003-4477-7367
  • Hide, Diana
  • Fernández-Iglesias, Anabel|||0000-0003-2364-6675
  • Gil, Mar
  • Barberá Bellés, Aurora|||0000-0002-6201-2643
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Martell, María|||0000-0002-0935-0029
Non-alcoholic steatohepatitis (NASH) is a common chronic liver disorder in developed countries, with the associated clinical complications driven by portal hypertension (PH). PH may precede fibrosis development, probably due to endothelial dysfunction at early stages of the disease. Our aim was to characterize liver sinusoidal endothelial cell (LSEC) dedifferentiation/capillarization and its contribution to PH in NASH, together with assessing statins capability to revert endothelial function improving early NASH stages. Sprague-Dawley rats were fed with high fat glucose-fructose diet (HFGFD), or control diet (CD) for 8 weeks and then treated with simvastatin (sim) (10 mg·kg·day), atorvastatin (ato) (10 mg·kg·day) or vehicle during 2 weeks. Biochemical, histological and hemodynamic determinations were carried out. Sinusoidal endothelial dysfunction was assessed in individualized sorted LSEC and hepatic stellate cells (HSC) from animal groups and in whole liver samples. HFGFD rats showed full NASH features without fibrosis but with significantly increased portal pressure compared with CD rats (10.47 ± 0.37 mmHg vs 8.30 ± 0.22 mmHg; p < 0.001). Moreover, HFGFD rats showed a higher percentage of capillarized (CD32b/CD11b) LSEC (8% vs 1%, p = 0.005) showing a contractile phenotype associated to HSC activation. Statin treatments caused a significant portal pressure reduction (sim: 9.29 ± 0.25 mmHg, p < 0.01; ato: 8.85 ± 0.30 mmHg, p < 0.001), NASH histology reversion, along with significant recovery of LSEC differentiation and a regression of HSC activation to a more quiescent phenotype. In an early NASH model without fibrosis with PH, LSEC transition to capillarization and HSC activation are reverted by statin treatment inducing portal pressure decrease and NASH features improvement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Villagrasa, Ares|||0000-0003-0928-0427
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Aguilera-Castro, Lara
  • Álvarez-López, Patricia|||0000-0003-4227-1987
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan|||0000-0002-1966-1947
  • Barber Caselles, Claudia|||0000-0003-4711-2731
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Biagetti, Betina|||0000-0002-8837-4343
  • Camps-Relats, Laura
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Cocera, Raul
  • Dopazo, Cristina|||0000-0001-6274-5911
  • Fernandez, Andrea
  • Jiménez, Cesar|||0000-0003-2455-2048
  • Jiménez, María M.
  • Jofra Castells, Mariona|||0000-0002-3034-4985
  • Gil, Clara
  • Gómez Gavara, Concepción|||0000-0001-8312-3273
  • Guanozzi, Danila
  • Guevara, Jorge A.
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Malagelada Prats, Carolina|||0000-0001-7097-1492
  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Mayorga, Luis
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Pando, Elizabeth|||0000-0001-6898-5502
  • Pérez-Lopez, Ana
  • Pigrau Pastor, Marc|||0000-0001-6801-3017
  • Prió, Alba
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Romero, Alba
  • Tasayco, Staphanie|||0000-0001-7867-349X
  • Vidal-Gonzalez, Judit
  • Vidal Piñeiro, Laura|||0000-0003-3757-3323
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Miret Campos Varela, Isabel
  • Villagrasa Vilella, Ares Aurora
  • Simon-Talero Horga, Macarena
  • Riveiro Barciela, Maria del Mar
  • Ventura Cots, Meritxell
  • Álvarez López, Patricia
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan
  • Barreira Diaz, Ana
  • Biagetti Biagetti, Betina
  • Camps-Relats, Laura
  • Cocera Rodriguez, Raul
  • Dopazo Taboada, Cristina
  • Fernandez Pujol, Andrea
  • Jimenez Hernandez, Cesar
  • Matarín Jiménez, Maria del Mar
  • Jofra, Mariona
  • Gil, Clara
  • Gomez Gavara, Concepción
  • Guevara Cubas, Jorge Alonso
  • Lobo Alvarez, Beatriz
  • Malagelada Prats, Carolina
  • Martínez Campreciós, Joan
  • Pando Rau, Elizabeth
  • Perez-Lopez, Ana
  • Prio, Alba
  • Rivera Esteban, Jesus Manuel
  • Romero, Alba
  • Tasayco Huaman, Stephanie Solange
  • Vidal Gonzalez, Judit
  • Vidal Piñeiro, Laura
  • Minguez Rosique, Beatriz
  • Genescà Ferrer, Joan
  • Ciudin Mihai, Andreea
  • Barber Caselles, Claudia
  • Augustin Recio, Salvador
  • Aguilera Castro, Lara
  • Guagnozzi, Danila
  • Miret Alomar, Enric
  • Pigrau Pastor, Marc
  • Mayorga Ayala, Luis Fernando
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury, Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JG is a recipient of a Research Intensification grant from the Instituto de Salud Carlos III, Spain. MST and MVC are recipients of a Juan Rodés grant from the Instituto de Salud Carlos III. The work was partially funded by grants PI17/00310, PI18/00947, PI18/00961, and PI19/00330 from Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future” – Una manera de hacer Europa). CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.